Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 2015

View Archived Issues

Adamas reports phase III data for ADS-5102 in levodopa-induced dyskinesia

Mundipharma enters option agreement with Skyepharma for inhaled triple combination SKP-2076

KamRAB demonstrates noninferiority to antirabies IgG reference product in pivotal trial

Revance's RT-001 reduces sweating in phase II axillary hyperhidrosis study

Agenus acquires novel cancer target discovery company PhosImmune

Small-molecule ghrelin receptor agonist shows efficacy for the treatment of CACS

Transgenic mouse and zebrafish models of leukemia

Research into genes linked with schizophrenia

SymBio files in Japan for additional cancer indications for bendamustine

No safety concerns in phase II breast cancer study with indoximod plus taxane chemotherapy

GSK reports mutant IDH1 inhibitors with activity against AML

FDA approves Eagle Pharmaceuticals' alcohol-free docetaxel

ALS can be identified by measuring four protein biomarkers in CSF

Urinary biopyrrin is a biomarker of idiopathic Parkinson's disease

Validation completed for CareDx's next-generation sequencing test Allosure

Teva and Takeda update on plans for Japanese joint venture

Honor roll for the Class of 2015: A review of this year's new drugs and biologics

Torii files Japanese NDA for ALK's cedar pollen SLIT-tablet

Bayer Schering Pharma patents MMP-12 inhibitors

WHO to review Emergency Use Assessment and Listing application for Merck & Co. Ebola vaccine

Shanghai Fochon Pharmaceutical describes EGFR inhibitors

Lundbeck reports PDE9 inhibitors

Redwood Bioscience presents anti-HER2 antibody-maytansine conjugates

Actelion Pharmaceuticals divulges T-type calcium channel blockers

Esteve patents dual sigma1 and mu-opioid receptors ligands

GluN2B receptor antagonists reported in Rugen Holdings (Cayman) patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...